Latest papers

[Infrastructure for new drug development to treat muscular dystrophy: current status of patient registration (remudy)].

Understanding drug safety and how to maximize it for patients.

[Methods for identification of adverse events of frequent drugs in regulatives use. Differences between questioning or spontaneous informing of the incidence].

Senate stalling derails bill to fix Canada's law on affordable generic medicines for developing countries.

Preclinical evaluation of juvenile toxicity.

Going viral.

A dearth of new meds.

[Studies with boceprevir].

Why do the same drugs look different? Pills, trade dress, and public health.

New technology assessment: riding the bullet train.

The lost decade of nesiritide.

[Now the National Board of Health is sleeping again--or is it a question of discrimination?].

Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma.

Prostate cancer: score one for validated targets.

Hepatitis C.

Approved Agents for Metastatic Breast Cancer

Interstitial cystitis/painful bladder syndrome.

Prucalopride. In chronic constipation: poorly documented risks.

Availability of comparative efficacy data at the time of drug approval in the United States.

Treatment for lupus, first in 50 years, offers modest benefits, hope to patients.